Fabletics and Hydrow Team up to Deliver Immersive Fitness Experience in Retail and Beyond

Fabletics and Hydrow Team up to Deliver Immersive Fitness Experience in Retail and Beyond

The World-Renowned Active Lifestyle Brand and Hydrow, the Live Outdoor Reality (LOR) Rower, Launch 360° Brand Partnership in Time for the Holidays

Fabletics today announced a strategic, long-term partnership with Hydrow, the immersive at-home rower with live and on-demand athlete-led workouts. With this partnership, the Fabletics community of more than two million VIP Members and guests of the brand’s 51 retail stores gain unrivaled access to the Hydrow experience.

As part of the Fabletics x Hydrow partnership, Fabletics members will be able to purchase a Hydrow at members only pricing, plus an exclusive accessories and gear package. Additionally, Hydrow is creating unique content and fitness milestone rewards specifically for the Fabletics VIP community. Hydrow plans to further enhance their offerings for Fabletics VIPs throughout 2021.

In addition, Fabletics will now serve as Hydrow’s official apparel partner. Fabletics will design and produce all Hydrow apparel, and Hydrow’s world-class trainers will exclusively wear Fabletics within all of Hydrow’s workout content.

“We sought out a partnership with Hydrow because we believe they offer one of the most exciting workout experiences available today,” commented Adam Goldenberg, Co-Founder and Co-CEO, TechStyle Fashion Group. “We know that 73% of our two million VIP Members are working out more than three times per week, and that they love trying something new. With Hydrow, we are bringing them the best workout they can get in 20 minutes – demonstrably more effective than cycling or running. We are thrilled to kick off this collaboration and bring Hydrow to our community.”

“Hydrow is committed to breaking barriers in rowing and making the sport accessible to everyone. Our partnership with Fabletics will help us continue to advance our mission,” commented Bruce Smith, CEO of Hydrow. “By collaborating with Fabletics’ loyal and expansive community, we will be able to bring the Hydrow experience to millions of people who are in search of a workout that not only pushes their body, but focuses their mind. We look forward to this meaningful partnership with Fabletics and to bringing them on board as our exclusive apparel partner.”

The Fabletics x Hydrow partnership goes live with the launch of a dedicated Hydrow experience on Fabletics.com and in-store Hydrow pop-up shops in seven Fabletics retail locations across the country on November 4th. The pop-ups will offer Fabletics members and guests the opportunity to experience Hydrow’s immersive concept and unmatched workout performance via demonstrations with Hydrow experts.

Hydrow’s patented immersive technology and 22-inch HD screen allow users to travel the world, no passport required. Hydrow users get the feel of being right on the river as they are transported from their living rooms to waterways around the globe. This unique immersive experience is coupled with game-changing workout performance – Hydrow users receive an unsurpassed full-body workout, in half the time as other cardio machines.

Fabletics x Hydrow will celebrate their new partnership throughout the quarter with a series of surprise-and-delight moments, which will

Read more

General plans campaign to deliver coronavirus vaccine quickly

The Pentagon general spearheading President Trump’s drive to ensure a coronavirus vaccine gets to the American people in record time said Tuesday that Operation Warp Speed can only work if there is full buy-in from the public when the vaccine becomes available.

Army Gen. Gustave Perna, a military logistics specialist who got a shoutout from Mr. Trump himself at last week’s presidential debate, described his mission at a session organized by the conservative Heritage Foundation was “our world’s best scientists and doctors working beside the world’s best military with the support of American industry and academia.”

“It’s the collective effort that will ensure we’re successful. I’m proud to be a part of it,” Gen. Perna said.

Operation Warp Speed is pushing ahead in the face of an at times angry political debate over the government’s handling of the virus crisis and whether the urgency of the mission will affect the safety of the process.

Thousands of volunteers will be needed after pharmaceutical giants AstraZeneca and Johnson & Johnson announced this week they were restarting U.S. clinical trials on their coronavirus vaccine candidates following a temporary stand-down over possible safety issues. Officials at Operation Warp Speed — a public-private partnership to develop therapeutics and ultimately a vaccine for COVID-19 — said locating a large number of volunteers for the trials is absolutely crucial.

In the past, about 5,000 to 8,000 people agreed to take part in clinical trials, Dr. Matthew Hepburn, head of program’s vaccine development, told the Heritage gathering.

“Our standard has been 30,000 volunteers for our clinical trials. We want to gather as much safety information as we possibly can,” Dr. Hepburn said Tuesday. “We want to know if [the vaccine candidates] work. The more people you enroll, the sooner you’re going to be able to evaluate the effectiveness.”

Dr. Hepburn said biotech firm Moderna has already completed its Phase 3 clinical trials with more than 30,000 volunteers enrolled in the testing. The New York-based pharmaceutical company Pfizer has signed up more than 40,000 people to take part in currently ongoing testing.

“That shows me that over 60,000 Americans have decided to say, ‘I will volunteer. I don’t know if I’m going to receive the vaccine or if I receive a placebo. But I’m going to do my part,’” Dr. Hepburn said. “We’re very proud of the spirit of volunteerism that we see in America.”

Medical researchers will be keeping in contact with those who received the initial COVID-19 vaccine candidates.

“The people that are vaccinated in the clinical trial now, our intention is to follow them for up to two years so we can get a better idea on that critically important question of duration of protection,” Dr. Hepburn said.

Past campaigns against viruses such as smallpox, polio and the measles made it possible for researchers to move more quickly to the coronavirus finish line, officials said.

“These efforts have gone on for decades. We stand on the shoulder of giants,” Dr. Hepburn said. “There was massive progress

Read more

Pfizer Says It Could Still Deliver A Covid-19 Vaccine In 2020

Pfizer executives expressed measured optimism Tuesday over the prospect of providing a coronavirus vaccine in 2020 as the pharma giant reported lower third-quarter profits due to disruption in healthcare that dented drug demand.

Pfizer Chief Executive Albert Bourla said the drug giant could supply some 40 million doses in the United States in 2020 if clinical testing proceeds as expected and regulators approve a vaccine.

“If all goes well, we will be ready to distribute an initial number of doses,” said Bourla, who pointed to a US government contract for Pfizer to supply 40 million doses by the end of this year and 100 million doses by March 2021.

But Bourla said the company still had not reached key benchmarks in assessing vaccine efficacy. Pfizer has said previously that it could have the data in October.

Bourla said the company expects to file for emergency use authorization for its Covid-19 vaccine in the third week of November, roughly in line with earlier timetables.

Asked if he was “bullish” the vaccine would work, Bourla said: “I’m not bullish a vaccine will work. I’m cautiously optimistic that the vaccine will work.”

Regarding earnings, Pfizer reported a 71 percent drop in profit to $2.2 billion. The year-ago period included a large gain connected to a transaction.

Pfizer reported lower third-quarter profits, in part due to lower pharma demand as patients' normal patterns of healthcare were disrupted due to Covid-19 Pfizer reported lower third-quarter profits, in part due to lower pharma demand as patients’ normal patterns of healthcare were disrupted due to Covid-19 Photo: AFP / DOMINICK REUTER

Revenues dipped four percent to $12.1 billion, missing analyst estimates.

Pfizer estimated a revenue hit of $500 million connected to Covid-19 due to lower pharma demand in China and fewer wellness visits from patients in the US.

The company saw an 11 percent drop in its hospital business in emerging markets, primarily due to fewer elective surgeries in China and shorter in-patient hospital stays in the country.

This effect was partially offset by increased demand for the Prevnar-13 vaccine for pneumonia “resulting from greater vaccine awareness for respiratory illnesses,” the company said.

Pfizer also cited strong performance in its biopharma business due to good sales for cancer drug Ibrance, anticoagulant Eliquis and other medications.

Shares edged up 0.1 percent to $37.97 in afternoon trading.

Source Article

Read more
  • Partner links